1 study found for:    NCT00585195
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Recruiting A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Systemic Anaplastic Large-Cell Lymphoma;   Neoplasms;   Anaplastic Lymphoma Kinase, Human;   NSCLC
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Ketoconazole

Indicates status has not been verified in more than two years